chevron_leftBack
As of 24 April 2025, MedRx Co., Ltd. has a market cap of $21.33M USD, ranking #29505 globally and #3452 in Japan. It ranks #2953 in the Healthcare sector, and #624 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$21.33MUSD
3.04B JPY
Enterprise Value
$7.43MUSD
1.06B JPY
Revenue (TTM)
$1.8MUSD
257.0M JPY
EBITDA (TTM)
-$5.28MUSD
-755.0M JPY
Net Income (TTM)
-$5.66MUSD
-806.0M JPY
EBITDA Margin
-294%
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Yonehiro Matsumura
open_in_new
Employees
22
Founded
2002
Website
medrx.co.jp
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 3.1% | 6.6% | -24% | -18% | -26% | -44% |
Upcoming Earnings
Earnings Date
Fri, May 9
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
4586
株式会社メドレックス
ISIN: JP3921220004
Shares Out.:
Shares Outstanding:
47.495M1
Shares Float:
44.019M2
|
66 JPY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About MedRx Co., Ltd.
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer’s disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
